The average NSE concentration in patients with NfT2DM after recovering from COVID-19 was significantly higher than in the group with NfT2DM before COVID-19, showing a difference of 4.6 ng/mL, indicating a 62% increase compared to the average NSE concentration in the pre-COVID-19 NfT2DM group. The gene discussed is ENO2; the disease is COVID-19.